COMMUNIQUÉS West-GlobeNewswire

CooperCompanies to Participate in the William Blair Growth Stock Conference
14/05/2024
SAN RAMON, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, will participate in the William Blair Growth Stock Conference on Wednesday, June 5, 2024. Dan [...]
GENFIT Reports First Quarter 2024 Financial Information
14/05/2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Information financière du premier trimestre 2024
14/05/2024
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2024 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des [...]
BioRestorative Therapies Provides First Quarter 2024 Business Update
14/05/2024
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today [...]
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
14/05/2024
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential [...]
Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results
14/05/2024
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
14/05/2024
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater [...]
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
14/05/2024
Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 [...]
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
14/05/2024
Initial Data from Ongoing MyPEAK™ - 1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE ™ -1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in Alignment with [...]
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
14/05/2024
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
14/05/2024
PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2024
14/05/2024
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial [...]
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
14/05/2024
Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host [...]
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
14/05/2024
Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected [...]
Iridex Reports First Quarter 2024 Financial Results
14/05/2024
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
14/05/2024
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, today reported [...]
TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
14/05/2024
Growing Body of Clinical Data from Ongoing Phase 2 Trial Suggests that Tacrolimus Inhalation Powder (TFF TAC) Could Represent an Important New Innovation for Optimizing Immunosuppressive Therapy in Lung Transplant [...]
NeuroPace to Participate in Two Healthcare Conferences in May
14/05/2024
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in [...]
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
14/05/2024
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD [...]

Pages